论文部分内容阅读
英《内科新闻》第11卷第36期(1979年)报道:对支气管哮喘,英国现有一种口服预防治疗法。 Kototifen(Zaditen)是由山道士药品有限公司研制,口服时具有抗过敏性。作用机理尚不清楚,但大约能抑制从肥大细胞释放组织胺及其他介质。因此,其作用类似色甘酸钠(Intal),但后者口服时无效。 Kototifen的效能已在长期临床试用中试验。据称,按规定服用此药时,哮喘发作的次数、严重度及发作时间均大大减少;减少了支气管扩张剂及类固醇的需要。可能需要服药数
The British “Medical News” Volume 11, No. 36 (1979) reported: for bronchial asthma, the United Kingdom there is a method of oral prophylaxis. Kototifen (Zaditen) was developed by Sandoz Pharmaceutical Co., Ltd. and is anti-allergic when taken orally. The mechanism of action is unclear, but about the inhibition of histamine and other mediators released from mast cells. Therefore, it acts like Intal, but the latter is ineffective when taken orally. The potency of Kototifen has been tested in long-term clinical trials. Allegedly, according to the provisions of taking this medicine, the number of asthma attacks, severity and onset time are greatly reduced; reduce the need for bronchodilators and steroids. It may take medication